A collaborative research centre has been set up by pharmaceutical company GSK, the European Bioinformatics Institute and the Wellcome Trust Sanger Institute.
The Centre for Therapeutic Target Validation, announced on 27 March, is based at the Wellcome Trust Genome Campus outside Cambridge. It is a public-private centre at which genomic information and Big Data will be used to speed up the discovery of new drugs.
A total of 50 researchers, drawn from all three organisations involved, will work at the centre. They will use data from genomics, proteomics, chemistry and disease biology in the EBI’s recently built innovation and translation suite and the Wellcome Trust Sanger Institute’s laboratories. The centre will share its data openly to promote the discovery of medicines.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.